Holen Sie sich die Stockscreener-App
5.96
3.22%
-0.245
Schlusskurs vom Vortag:
$6.205
Offen:
$6.17
24-Stunden-Volumen:
364.91K
Relative Volume:
0.45
Marktkapitalisierung:
$311.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.14M
KGV:
-6.4783
EPS:
-0.92
Netto-Cashflow:
$-12.64M
1W Leistung:
-9.02%
1M Leistung:
+42.64%
6M Leistung:
+150.21%
1J Leistung:
+207.95%
1-Tages-Spanne:
$5.8501
$6.4799
1-Wochen-Bereich:
$6.00
$7.73
52-Wochen-Spanne:
$1.34
$7.73
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Vergleichen Sie IMMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
5.92 | 326.98M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.90 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.00 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
849.08 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.26 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.98 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World
Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in
Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn
FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis
Immix Biopharma CFO Gabriel Morris buys $5k in shares By Investing.com - Investing.com Canada
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares By Investing.com - Investing.com Canada
Immix Biopharma CFO Gabriel Morris buys $5k in shares - Investing.com
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares - Investing.com
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright - Investing.com Australia
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright By Investing.com - Investing.com South Africa
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Sahm
IMMX Analyst Rating Update: HC Wainwright Raises Price Target to - GuruFocus
Immix Biopharma closes $93.7 million public offering By Investing.com - Investing.com Canada
Immix Biopharma closes $93.7 million public offering - Investing.com
Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants - marketscreener.com
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Immix Biopharma prices $100M equity raise via common stock and warrant offering - MSN
Taking the lead: Immix Biopharma Inc (IMMX) - setenews.com
Immix Biopharma — Promising NEXICART-2 data; runway extended - Smartkarma
Immix Biopharma Enters Underwriting Agreement with Morgan Stanley - TipRanks
Form 424B5 Immix Biopharma, Inc. - StreetInsider
Immix Biopharma’s Market Dynamics Amid Economic Shifts - timothysykes.com
Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026 - Nasdaq
Immix Biopharma Prices $100 Million Offering - marketscreener.com
Immix Biopharma Announces Positive Phase 2 Trial Results - TipRanks
Form FWP Immix Biopharma, Inc. Filed by: Immix Biopharma, Inc. - StreetInsider
Immix Biopharma, Inc. Announces Positive Phase 2 NXC-201 Results - TradingView — Track All Markets
Immix Biopharma prices $100 million public offering to fund AL amyloidosis drug - Investing.com Nigeria
Immix Biopharma reports 75% complete response rate for NXC-201 By Investing.com - Investing.com Nigeria
Immix Biopharma reports 75% complete response rate for NXC-201 - Investing.com India
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Investing News Network
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Immix Biopharma prices offering of 19.1 million shares at $5.10 per share - marketscreener.com
Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share - TradingView — Track All Markets
Immix Biopharma (IMMX) sets price for upsized $100M stock and pre-funded warrant offering - Stock Titan
Immix Biopharma (IMMX) reports 75% CR at ASH 2025, plans 2026 NXC-201 BLA - Stock Titan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Is Immix Biopharma Inc (IMMX) positioned for future growth? - Setenews
Immix Biopharma, Inc.'s (NASDAQ:IMMX) market cap rose US$18m last week; retail investors who hold 56% profited and so did insiders - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Trading 4.5% Higher – What’s Next? - Defense World
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immix Biopharma Inc-Aktie (IMMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
0.42%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):